Produção Nacional
Revisado por pares
Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases
2022; Springer Science+Business Media; Volume: 28; Issue: 2 Linguagem: Inglês
10.1007/s13365-022-01066-3
ISSN1538-2443
AutoresCláudia Cristina Ferreira Vasconcelos, Mariana Beiral Hämmerle, Déborah Santos Sales, Fernanda Cristina Rueda Lopes, Patrícia Pinheiro, Elisa Gutman Gouvea, Manuella Caroline Dutra Frazão Alves, Tayane Vasconcellos Pereira, Sergio L. Schmidt, Regina Maria Papais Alvarenga, Karina Lebeis Pires,
Tópico(s)Peripheral Neuropathies and Disorders
ResumoOlfactory dysfunction is reported frequently in patients with coronavirus disease 2019. However, an effective treatment for this dysfunction is unknown. The present study evaluated carbamazepine as a treatment option for olfactory dysfunction based on its use in cases of neuralgia, especially of the V cranial nerve. The study included 10 patients with coronavirus disease with olfactory complaints who were part of a cohort of 172 coronavirus disease patients monitored for late neurological manifestations. Carbamazepine was administered for 11 weeks. The adverse effects reported were drowsiness (9/10) and dizziness (2/10); 9 of the 10 patients reported improved olfactory function after carbamazepine treatment. While the role of carbamazepine in the control of post-coronavirus disease olfactory dysfunction could not be confirmed in this study, the satisfactory response observed in most patients in this series suggests that further studies are warranted.
Referência(s)